ScreenerHero

MRVI Maravai LifeSciences Holdings, Inc.

NAS · US · Healthcare · Biotechnology · maravai.com
7.430USD-5.35%Mkt Cap: 2.75B $P/E: —

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.75B USD
Enterprise Value1.47B USD
Revenue (TTM)208.78M USD
Gross Profit33.99M USD
Net Income (TTM)-130.77M USD
Revenue/Share1.43 USD
Last Price7.430 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees415
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-77.99
PEG—
EV/EBITDA-74.38
EV/Revenue7.03
P/S13.93
P/B5.71
EPS (TTM)-0.49
EPS (Forward)-0.10
52W Range
2.54571% of range9.420
52W High9.420 USD
52W Low2.545 USD
Profitability
Gross Margin18.30%
Oper. Margin-29.40%
EBITDA Margin-9.46%
Profit Margin-70.41%
ROE-61.58%
ROA-16.97%
Growth
Revenue Growth8.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-57.57M USD
CapEx (TTM)13.15M USD
FCF Margin-1.74%
FCF Yield-0.13%
Net Debt148.01M USD
Net Debt/EBITDA-7.50
Balance Sheet
Debt/Equity1.72
Current Ratio4.05
Quick Ratio2.63
Book Value/Sh1.37 USD
Cash/Share0.47 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.833 USD
Upside (mean)+5.4%
Target Range7.000 USD – 9.000 USD
7.000+5.4% to mean9.000
# Analysts6
Ownership
Shares Out.148.99M
Float106.43M
Insiders7.25%
Institutions98.96%
Short Interest
Short Ratio2.6d
Short % Float9.84%
Short % Out.8.30%
Shares Short12.37M
Short (prev mo.)9.38M
Technical
SMA 507.109 (+4.5%)
SMA 2004.873 (+52.5%)
Beta0.54
S&P 52W Chg16.45%
Avg Vol (30d)3.46M
Avg Vol (10d)2.36M
Technical Indicators
RSI (14)50.6
MACD0.2443
MACD Signal0.2310
MACD Hist.+0.0133
BB Upper8.335 USD
BB Middle7.366 USD
BB Lower6.398 USD
BB Width26.30%
ATR (14)0.4798 USD
Vol Ratio (20d)1.84x